Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:

Time Point (h)

Treatment: ●─●─● Treatment A   ◆─◆─◆ Treatment B   ▲─▲─▲ Treatment C

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 μg of levothyroxine; Treatment B: 6 tablets of 100 μg of levothyroxine;
Treatment C: 3 tablets of 200 μg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.9.sas

10DEC2014 00:20

Merck Serono   Page 18 of 42
EMR 200125-002   Confidential
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 μg of levothyroxine; Treatment B: 6 tablets of 100 μg of levothyroxine;
Treatment C: 3 tablets of 200 μg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.9.sas

10DEC2014 00:20

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 μg of levothyroxine; Treatment B: 6 tablets of 100 μg of levothyroxine;
Treatment C: 3 tablets of 200 μg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.9.sas

10DEC2014 00:20

Merck Serono Page 20 of 42

EMR 200125-002 Confidential

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number: :

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.9.sas

10DEC2014 00:20

Merck Serono   Page 21 of 42
EMR 200125-002   Confidential
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine;   Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.9.sas

10DEC2014 00:20

Merck Serono   Page 22 of 42
EMR 200125-002   Confidential
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.9.sas

10DEC2014 00:20

Merck Serono   Page 23 of 42
EMR 200125-002   Confidential
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number: :

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine;   Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.9.sas

10DEC2014 00:20

Merck Serono   Page 24 of 42
EMR 200125-002   Confidential
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number: :

θ:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.9.sas

10DEC2014 00:20

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number: ⸱⸱⸱

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.9.sas

10DEC2014 00:20

Merck Serono   Page 26 of 42
EMR 200125-002   Confidential

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 μg of levothyroxine; Treatment B: 6 tablets of 100 μg of levothyroxine;
Treatment C: 3 tablets of 200 μg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.9.sas

10DEC2014 00:20

Merck Serono   Page 27 of 42
EMR 200125-002   Confidential
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.9.sas

10DEC2014 00:20

Merck Serono   Page 28 of 42
EMR 200125-002   Confidential
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number: ⸱

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 μg of levothyroxine; Treatment B: 6 tablets of 100 μg of levothyroxine;
Treatment C: 3 tablets of 200 μg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.9.sas

10DEC2014 00:20

Merck Serono   Page 29 of 42
EMR 200125-002   Confidential

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.9.sas

10DEC2014 00:20

Merck Serono　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　Page 30 of 42
EMR 200125-002　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　Confidential
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 μg of levothyroxine;　Treatment B: 6 tablets of 100 μg of levothyroxine;
Treatment C: 3 tablets of 200 μg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.9.sas

10DEC2014 00:20

Merck Serono   Page 31 of 42
EMR 200125-002   Confidential
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number: 1

θ:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 μg of levothyroxine; Treatment B: 6 tablets of 100 μg of levothyroxine;
Treatment C: 3 tablets of 200 μg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.9.sas

10DEC2014 00:20

Merck Serono   Page 32 of 42
EMR 200125-002   Confidential

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.9.sas

10DEC2014 00:20

Merck Serono   Page 33 of 42
EMR 200125-002   Confidential
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number: 1

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.9.sas

10DEC2014 00:20

Merck Serono   Page 34 of 42
EMR 200125-002   Confidential
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.9.sas

10DEC2014 00:20

Merck Serono　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　Page 35 of 42
EMR 200125-002　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　Confidential
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number: 1

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine;　Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.9.sas

10DEC2014 00:20

Merck Serono   Page 36 of 42
EMR 200125-002   Confidential

Figure 15.4.2.9 Concentration–Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine;   Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
.15.4.2.9.sas

                                                                  10DEC2014 00:20

Merck Serono   Page 37 of 42
EMR 200125-002   Confidential
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine;   Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.9.sas

10DEC2014 00:20

Merck Serono Page 38 of 42
EMR 200125-002 Confidential
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.9.sas

10DEC2014 00:20

Merck Serono　　　　　　　　　　　　　　　　　　　　　　　　　　　　　Page 39 of 42
EMR 200125-002　　　　　　　　　　　　　　　　　　　　　　　　　　　　Confidential
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 μg of levothyroxine; Treatment B: 6 tablets of 100 μg of levothyroxine;
Treatment C: 3 tablets of 200 μg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.9.sas

10DEC2014 00:20

Merck Serono   Page 40 of 42
EMR 200125-002   Confidential
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 μg of levothyroxine; Treatment B: 6 tablets of 100 μg of levothyroxine;
Treatment C: 3 tablets of 200 μg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.9.sas

10DEC2014 00:20

Merck Serono   Page 41 of 42
EMR 200125-002   Confidential
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 μg of levothyroxine; Treatment B: 6 tablets of 100 μg of levothyroxine;
Treatment C: 3 tablets of 200 μg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.9.sas

10DEC2014 00:20

Merck Serono   Page 42 of 42
EMR 200125-002   Confidential
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.9.sas

10DEC2014 00:20

Merck Serono   Page 1 of 42
EMR 200125-002   Confidential
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values)(Safety Population)

Subject ID/Random Number:

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

10DEC2014 00:20

Merck Serono   Page 2 of 42
EMR 200125-002   Confidential
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values)(Safety Population)
Subject ID/Random Number: 1

Treatment: ●—●—● Treatment A   ◆—◆—◆ Treatment B   ▲—▲—▲ Treatment C

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 μg of levothyroxine; Treatment B: 6 tablets of 100 μg of levothyroxine;
Treatment C: 3 tablets of 200 μg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas
                                                                          10DEC2014 00:20

Merck Serono   Page 3 of 42
EMR 200125-002   Confidential
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values)(Safety Population)

Subject ID/Random Number:

Time Point (h)

Treatment: ●─●─● Treatment A   ◆─◆─◆ Treatment B   ▲─▲─▲ Treatment C

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

10DEC2014 00:20

Merck Serono   Page 4 of 42
EMR 200125-002   Confidential
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values)(Safety Population)

Subject ID/Random Number: 1

Treatment: ●—●—● Treatment A   ◆—◆—◆ Treatment B   ▲—▲—▲ Treatment C

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine;   Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

10DEC2014 00:20

Merck Serono　　　　　　　　　　　　　　　　　　　　　　　　Page 5 of 42
EMR 200125-002　　　　　　　　　　　　　　　　　　　　　　　　Confidential
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values)(Safety Population)

Subject ID/Random Number:

Time Point (h)

Treatment:　●—●—● Treatment A　◆—◆—◆ Treatment B　▲—▲—▲ Treatment C

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine;　Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

10DEC2014 00:20

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values)(Safety Population)

Subject ID/Random Number:

Treatment: ●─●─● Treatment B   ▲─▲─▲ Treatment C

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 μg of levothyroxine; Treatment B: 6 tablets of 100 μg of levothyroxine;
Treatment C: 3 tablets of 200 μg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

10DEC2014 00:20

Merck Serono   Page 7 of 42
EMR 200125-002   Confidential
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values)(Safety Population)
                                     Subject ID/Random Number:

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine;   Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

                                                                                     10DEC2014 00:20

Merck Serono   Page 8 of 42
EMR 200125-002   Confidential
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values)(Safety Population)
Subject ID/Random Number:

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine;   Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

10DEC2014 00:20

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values)(Safety Population)

Subject ID/Random Number:

Time Point (h)

Treatment:　●─●─● Treatment A　◆─◆─◆ Treatment B　▲─▲─▲ Treatment C

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine;　Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

10DEC2014 00:20

Merck Serono   Page 10 of 42
EMR 200125-002   Confidential
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values)(Safety Population)

Subject ID/Random Number:

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 μg of levothyroxine;   Treatment B: 6 tablets of 100 μg of levothyroxine;
Treatment C: 3 tablets of 200 μg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

10DEC2014 00:20

Merck Serono
EMR 200125-002

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values)(Safety Population)

Subject ID/Random Number:

Treatment: ●─●─● Treatment A ◆─◆─◆ Treatment B ▲─▲─▲ Treatment C

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

10DEC2014 00:20

Merck Serono   Page 12 of 42
EMR 200125-002   Confidential
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values)(Safety Population)
Subject ID/Random Number:

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine;   Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

10DEC2014 00:20

Merck Serono   Page 13 of 42
EMR 200125-002   Confidential
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values)(Safety Population)
Subject ID/Random Number: ⸝

Treatment: ●―●―● Treatment A   ◆―◆―◆ Treatment B   ▲―▲―▲ Treatment C

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

10DEC2014 00:20

Merck Serono
EMR 200125-002

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values)(Safety Population)

Subject ID/Random Number: .

Time Point (h)

Treatment: ●─●─● Treatment A   ◆─◆─◆ Treatment B   ▲─▲─▲ Treatment C

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

10DEC2014 00:20

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values)(Safety Population)

Subject ID/Random Number: 1

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine;   Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

10DEC2014 00:20

Merck Serono   Page 16 of 42
EMR 200125-002   Confidential
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values)(Safety Population)

Subject ID/Random Number: :

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 μg of levothyroxine; Treatment B: 6 tablets of 100 μg of levothyroxine;
Treatment C: 3 tablets of 200 μg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

10DEC2014 00:20

Merck Serono   Page 17 of 42
EMR 200125-002   Confidential
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values)(Safety Population)

Subject ID/Random Number: 1

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

10DEC2014 00:20

Merck Serono   Page 18 of 42
EMR 200125-002   Confidential
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values)(Safety Population)

Subject ID/Random Number:

Treatment: ●──●──● Treatment A   ◆──◆──◆ Treatment B   ▲──▲──▲ Treatment C

ө:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 μg of levothyroxine; Treatment B: 6 tablets of 100 μg of levothyroxine;
Treatment C: 3 tablets of 200 μg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

10DEC2014 00:20

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values)(Safety Population)

Subject ID/Random Number:

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

10DEC2014 00:20

Merck Serono   Page 20 of 42
EMR 200125-002   Confidential
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values)(Safety Population)

Subject ID/Random Number: ı·

Treatment: ●—●—● Treatment A   ◆—◆—◆ Treatment B   ▲—▲—▲ Treatment C

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

10DEC2014 00:20

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values)(Safety Population)

Subject ID/Random Number: }

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine;   Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

10DEC2014 00:20

Merck Serono   Page 22 of 42
EMR 200125-002   Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values) (Safety Population)

Subject ID/Random Number:

Time Point (h)

Treatment: ●─●─● Treatment A   ◆─◆─◆ Treatment B   ▲─▲─▲ Treatment C

θ:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine;   Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas
                                                           10DEC2014 00:20

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values)(Safety Population)

Subject ID/Random Number:

Time Point (h)

Treatment: ◆—◆—◆ Treatment B

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

10DEC2014 00:20

Merck Serono
EMR 200125-002

Page 24 of 42
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values)(Safety Population)

Subject ID/Random Number:

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

10DEC2014 00:20

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values)(Safety Population)

Subject ID/Random Number:

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 μg of levothyroxine; Treatment B: 6 tablets of 100 μg of levothyroxine;
Treatment C: 3 tablets of 200 μg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

10DEC2014 00:20

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values)(Safety Population)

Subject ID/Random Number:

Treatment: ●─●─● Treatment A   ◆─◆─◆ Treatment B   ▲─▲─▲ Treatment C

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 μg of levothyroxine; Treatment B: 6 tablets of 100 μg of levothyroxine;
Treatment C: 3 tablets of 200 μg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

10DEC2014 00:20

Merck Serono   Page 27 of 42
EMR 200125-002   Confidential
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values)(Safety Population)

Subject ID/Random Number:

Time Point (h)

Treatment: ●—●—● Treatment A   ◆—◆—◆ Treatment B   ▲—▲—▲ Treatment C

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

                                                                                                            10DEC2014 00:20

Merck Serono Page 28 of 42
EMR 200125-002 Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values)(Safety Population)

Subject ID/Random Number:

Time Point (h)

Treatment: ●─●─● Treatment A ◆─◆─◆ Treatment B ▲─▲─▲ Treatment C

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

10DEC2014 00:20

Merck Serono   Page 29 of 42
EMR 200125-002   Confidential
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values)(Safety Population)
Subject ID/Random Number:

Time Point (h)

Treatment: ●─●─● Treatment A   ◆─◆─◆ Treatment B   ▲─▲─▲ Treatment C

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

10DEC2014 00:20

Figure 15.4;2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values)(Safety Population)

Subject ID/Random Number:

Time Point (h)

Treatment: ●─●─● Treatment A   ◆─◆─◆ Treatment B   ▲─▲─▲ Treatment C

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

10DEC2014 00:20

Merck Serono   Page 31 of 42
EMR 200125-002   Confidential
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values)(Safety Population)

Subject ID/Random Number:

Time Point (h)

Treatment: ●─●─● Treatment A   ◆─◆─◆ Treatment B   ▲─▲─▲ Treatment C

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

10DEC2014 00:20

Levothyroxine
EMR 200125-002

Dosage Form Proportion: ... ... EMR200125-002 Page 556 of 658 ions (50 µg, 100 µg, and 200 µg Tablets) in Fasted
State

Merck Serono
EMR 200125-002

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values)(Safety Population)

Subject ID/Random Number:

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

10DEC2014 00:20

Merck Serono
EMR 200125-002

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values)(Safety Population)

Subject ID/Random Number:

Time Point (h)

Treatment: ●━●━● Treatment A   ◆━◆━◆ Treatment B   ▲━▲━▲ Treatment C

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

10DEC2014 00:20

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T4 Values)(Safety Population)

Subject ID/Random Number:

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 μg of levothyroxine; Treatment B: 6 tablets of 100 μg of levothyroxine;
Treatment C: 3 tablets of 200 μg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.10.sas

10DEC2014 00:20

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values)(Safety Population)
Subject ID/Random Number:

Time Point (h)

Treatment: ◆━◆━◆ Treatment B

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 μg of levothyroxine; Treatment B: 6 tablets of 100 μg of levothyroxine;
Treatment C: 3 tablets of 200 μg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

10DEC2014 00:20

Merck Serono   Page 36 of 42
EMR 200125-002   Confidential
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values)(Safety Population)

Subject ID/Random Number:

Treatment: ●—●—● Treatment A   ◆—◆—◆ Treatment B   ▲—▲—▲ Treatment C

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

                                                                               10DEC2014 00:20

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values)(Safety Population)

Subject ID/Random Number:

Time Point (h)

Treatment: ●─●─● Treatment A   ◆─◆─◆ Treatment B   ▲─▲─▲ Treatment C

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

10DEC2014 00:20

Merck Serono   Page 38 of 42
EMR 200125-002   Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values)(Safety Population)

Subject ID/Random Number:

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values)(Safety Population)

Subject ID/Random Number:

Treatment: ●─●─● Treatment A   ◆─◆─◆ Treatment B   ▲─▲─▲ Treatment C

θ:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

10DEC2014 00:20

Merck Serono　　　　　　　　　　　　　　　　　　　　　　　　　　　Page 40 of 42
EMR 200125-002　　　　　　　　　　　　　　　　　　　　　　　　　　Confidential
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values)(Safety Population)
　　　　　　　　　　　　　Subject ID/Random Number: .

Treatment:　▲—▲—▲　Treatment C
θ:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine;　Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　10DEC2014 00:20

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values)(Safety Population)

Subject ID/Random Number: :

Treatment: ●─●─● Treatment A   ◆─◆─◆ Treatment B   ▲─▲─▲ Treatment C

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

10DEC2014 00:20

Merck Serono   Page 42 of 42
EMR 200125-002   Confidential
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(for Total T4 Values)(Safety Population)
                                  Subject ID/Random Number:

Time Point (h)

Treatment: ●—●—● Treatment A   ◆—◆—◆ Treatment B   ▲—▲—▲ Treatment C

@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 μg of levothyroxine; Treatment B: 6 tablets of 100 μg of levothyroxine;
Treatment C: 3 tablets of 200 μg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

   10DEC2014 00:20

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values) (Safety Population)

Subject ID/Random Number:

Treatment: ●—●—● Treatment A ◆—◆—◆ Treatment B ▲—▲—▲ Treatment C

@:Subjects excluded from PK Population;
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.11.sas

10DEC2014 00:20

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:

@:Subjects excluded from PK Population;
Treatment A: 12 tablets of 50 μg of levothyroxine;   Treatment B: 6 tablets of 100 μg of levothyroxine;
Treatment C: 3 tablets of 200 μg of levothyroxine.
/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.11.sas

10DEC2014 00:20

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:

@:Subjects excluded from PK Population;
Treatment A: 12 tablets of 50 μg of levothyroxine;   Treatment B: 6 tablets of 100 μg of levothyroxine;
Treatment C: 3 tablets of 200 μg of levothyroxine.
/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.11.sas

10DEC2014 00:20

Merck Serono   Page 4 of 42
EMR 200125-002   Confidential
Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:

@:Subjects excluded from PK Population;
Treatment A: 12 tablets of 50 μg of levothyroxine;   Treatment B: 6 tablets of 100 μg of levothyroxine;
Treatment C: 3 tablets of 200 μg of levothyroxine.
/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.11.sas

10DEC2014 00:20

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number: :

@:Subjects excluded from PK Population;
Treatment A: 12 tablets of 50 µg of levothyroxine;   Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.11.sas

10DEC2014 00:20

Merck Serono   Page 6 of 42
EMR 200125-002   Confidential
Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:

@:Subjects excluded from PK Population;
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.11.sas

10DEC2014 00:20

Merck Serono   Page 7 of 42
EMR 200125-002   Confidential
Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:

@:Subjects excluded from PK Population;
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.11.sas

10DEC2014 00:20

Merck Serono   Page 8 of 42
EMR 200125-002   Confidential
Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number: :

@:Subjects excluded from PK Population;
Treatment A: 12 tablets of 50 µg of levothyroxine;　Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.11.sas

10DEC2014 00:20

Merck Serono   Page 9 of 42
EMR 200125-002   Confidential
Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number· ˙˙

@:Subjects excluded from PK Population;
Treatment A: 12 tablets of 50 μg of levothyroxine; Treatment B: 6 tablets of 100 μg of levothyroxine;
Treatment C: 3 tablets of 200 μg of levothyroxine.
/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.11.sas

10DEC2014 00:20

Merck Serono   Page 10 of 42
EMR 200125-002   Confidential
Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number: ▲

Time Point (h)

Treatment: ●─●─● Treatment A   ◆─◆─◆ Treatment B   ▲─▲─▲ Treatment C

θ:Subjects excluded from PK Population;
Treatment A: 12 tablets of 50 μg of levothyroxine; Treatment B: 6 tablets of 100 μg of levothyroxine;
Treatment C: 3 tablets of 200 μg of levothyroxine.
/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.11.sas

10DEC2014 00:20

Merck Serono   Page 11 of 42
EMR 200125-002   Confidential

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:

@:Subjects excluded from PK Population;
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.11.sas

10DEC2014 00:20

Merck Serono   Page 12 of 42
EMR 200125-002   Confidential
Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:

@:Subjects excluded from PK Population;
Treatment A: 12 tablets of 50 µg of levothyroxine;   Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.11.sas

10DEC2014 00:20

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:

@:Subjects excluded from PK Population;
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.11.sas

10DEC2014 00:20

Merck Serono   Page 14 of 42
EMR 200125-002   Confidential
Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number: ⟨⟩

@:Subjects excluded from PK Population;
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.11.sas

10DEC2014 00:20

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number: 1

@:Subjects excluded from PK Population;
Treatment A: 12 tablets of 50 µg of levothyroxine;   Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.11.sas

10DEC2014 00:20

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number: :

@:Subjects excluded from PK Population;
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.11.sas

10DEC2014 00:20

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:

Time Point (h)

Treatment: ●─●─● Treatment A   ◆─◆─◆ Treatment B   ▲─▲─▲ Treatment C

@:Subjects excluded from PK Population;
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.11.sas

10DEC2014 00:20

Merck Serono   Page 18 of 42
EMR 200125-002   Confidential
Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:

@:Subjects excluded from PK Population;
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.11.sas

10DEC2014 00:20

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number: ˉ

@:Subjects excluded from PK Population;
Treatment A: 12 tablets of 50 μg of levothyroxine; Treatment B: 6 tablets of 100 μg of levothyroxine;
Treatment C: 3 tablets of 200 μg of levothyroxine.
/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.11.sas

10DEC2014 00:20

Merck Serono   Page 20 of 42
EMR 200125-002   Confidential
Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number: 1

@:Subjects excluded from PK Population;
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.11.sas

10DEC2014 00:20

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:

@:Subjects excluded from PK Population;
Treatment A: 12 tablets of 50 μg of levothyroxine; Treatment B: 6 tablets of 100 μg of levothyroxine;
Treatment C: 3 tablets of 200 μg of levothyroxine.
/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.11.sas

10DEC2014 00:20

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:

@:Subjects excluded from PK Population;
Treatment A: 12 tablets of 50 µg of levothyroxine;   Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.11.sas

10DEC2014 00:20

Merck Serono
EMR 200125-002

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number: ˙

Treatment: ◆—◆—◆ Treatment B

@:Subjects excluded from PK Population;
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.11.sas

10DEC2014 00:20

Merck Serono   Page 24 of 42
EMR 200125-002   Confidential
Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:

@:Subjects excluded from PK Population;
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.11.sas

10DEC2014 00:20

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:

@:Subjects excluded from PK Population;
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.11.sas

10DEC2014 00:20

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:

@:Subjects excluded from PK Population;
Treatment A: 12 tablets of 50 μg of levothyroxine;   Treatment B: 6 tablets of 100 μg of levothyroxine;
Treatment C: 3 tablets of 200 μg of levothyroxine.
/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.11.sas

10DEC2014 00:20

Merck Serono   Page 28 of 42
EMR 200125-002   Confidential
Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:

@:Subjects excluded from PK Population;
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.11.sas

10DEC2014 00:20

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number: ˙

@:Subjects excluded from PK Population;
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.11.sas

10DEC2014 00:20

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number: :

@:Subjects excluded from PK Population;
Treatment A: 12 tablets of 50 μg of levothyroxine; Treatment B: 6 tablets of 100 μg of levothyroxine;
Treatment C: 3 tablets of 200 μg of levothyroxine.
/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.11.sas

10DEC2014 00:20

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:

Treatment: ●─●─● Treatment A   ◆─◆─◆ Treatment B   ▲─▲─▲ Treatment C

θ:Subjects excluded from PK Population;
Treatment A: 12 tablets of 50 μg of levothyroxine; Treatment B: 6 tablets of 100 μg of levothyroxine;
Treatment C: 3 tablets of 200 μg of levothyroxine.
/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.11.sas

10DEC2014 00:20

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:

Time Point (h)

Treatment: ●─●─● Treatment A   ◆─◆─◆ Treatment B   ▲─▲─▲ Treatment C

@:Subjects excluded from PK Population;
Treatment A: 12 tablets of 50 μg of levothyroxine; Treatment B: 6 tablets of 100 μg of levothyroxine;
Treatment C: 3 tablets of 200 μg of levothyroxine.
/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.11.sas

10DEC2014 00:20